Molecular profile and targeted therapies for ovarian clear cell ovarian cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ovarian clear cell carcinoma (OCCC) is a distinct epithelial ovarian cancer subtype.
• OCCC exhibits unique molecular features, including frequent ARID1A loss and PIK3CA activation.
• This subtype is notably resistant to conventional platinum-based chemotherapy in advanced stages.

Purpose of the Study:

• To review the unique molecular features of OCCC.
• To discuss emerging targeted therapies and their potential in OCCC.
• To highlight the need for histology-specific therapeutic strategies informed by molecular profiling.

Main Methods:

• Literature review of OCCC molecular hallmarks.
• Analysis of emerging targeted therapies including anti-angiogenic agents, immune checkpoint inhibitors, ATR and PI3K pathway inhibitors, and antibody-drug conjugates.
• Examination of clinical trial data, particularly early-phase trials, for OCCC treatment efficacy.

Main Results:

• Frequent ARID1A loss and PIK3CA activation are key molecular hallmarks contributing to OCCC tumorigenesis.
• Targeted therapies show promising activity in molecularly defined OCCC subgroups.
• Evidence for most emerging therapies is limited to early-phase trials.

Conclusions:

• OCCC requires histology-specific therapeutic strategies due to its rarity and chemoresistance.
• Molecular profiling is crucial for guiding treatment decisions in OCCC.
• Biomarker-driven therapies and combination regimens hold potential to improve outcomes for OCCC patients.